• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Saturday, August 2, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Anti-parasitic drug to treat scabies on mass scale in Solomon Islands

Bioengineer by Bioengineer
August 24, 2022
in Health
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

An anti-parasitic drug will be rolled out on mass scale in the Solomon Islands to prevent scabies, a contagious, intensely itchy skin condition that affects a third of the nation’s children.

Anti-parasitic drug to treat scabies on mass scale in Solomon Islands

Credit: Murdoch Children’s Research Institute

An anti-parasitic drug will be rolled out on mass scale in the Solomon Islands to prevent scabies, a contagious, intensely itchy skin condition that affects a third of the nation’s children.

Murdoch Children’s Research Institute’s Sarah Andersson and Professor Andrew Steer from the World Scabies Program are leading the mass drug administration (MDA) program with the Solomon Islands’ Ministry of Health and Medical Services, which will deliver ivermectin to the whole population. It’s the first country-wide MDA in the world for the treatment of scabies.

After a successful trial in Fiji, led by the Murdoch Children’s, the Kirby Institute at UNSW Sydney and the Ministry of Health and Medical Services of Fiji, where ivermectin was administered to over 130,000 Fijians, the program is now being delivered on a mass scale to a whole country, a world first, in the Solomon Islands where scabies is a significant public health problem.  

Scabies is caused by a mite that burrows into the skin. The highly contagious disease causes itching, which can lead to complications such as severe skin infections and serious bacterial infections, bloodstream infections, kidney failure and heart disease.

The most common symptoms of scabies are intense itching and a pimple-like rash, and it can be cured with medications that are safe and affordable.

“Scabies affects everyone, especially young children,” Ms Andersson, program manager said. Rolling out the treatment for scabies to all communities in the Solomon Islands at the same time will contribute significantly to stopping the spread of scabies and preventing this debilitating condition.”

About a quarter of all people in the Solomon Islands have scabies at any one time, and children have the highest burden of disease with a third of children under 10 years affected. 

Professor Steer said, “our research shows MDA could reduce the prevalence of scabies by 90 per cent after just one treatment, which could have a huge impact on children in the region.

“Research from the Murdoch Children’s SHIFT trial and Big SHIFT trial has also shown that reducing scabies prevalence through MDA can also reduce skin infections such as impetigo (a common bacterial infection) up to 65 per cent and hospital admissions due to skin infections more than 15 per cent.”

Ms Andersson said the entire Solomon Islands population would be treated for scabies regardless of age and gender, and even people without scabies could receive ivermectin as a preventative measure. Vulnerable groups including babies, small children and pregnant women would also receive treatment in the form of a cream applied to their skin.

The Solomon Islands scabies MDA program is supported by the World Scabies Program, and initiative of the Murdoch Children’s, thanks to a $10 million grant from the Macquarie Group’s 50th anniversary philanthropic commitment to addressing social needs. The World Health Organization (WHO) has also contributed some funds for training.

Available for interview:

Sarah Andersson, Murdoch Children’s World Scabies Program (WSP) Program Manager
Professor Andrew Steer, Murdoch Children’s Infection and Immunity Theme Director



Method of Research

Observational study

Subject of Research

People

Share12Tweet8Share2ShareShareShare2

Related Posts

Special Collection: 2024 Aging Innovation Conference

Special Collection: 2024 Aging Innovation Conference

August 2, 2025
Magnesium Implants Boost Bone-Immune Health In Vitro

Magnesium Implants Boost Bone-Immune Health In Vitro

August 2, 2025

GBA1 Variants’ Impact on Parkinson’s: In Silico Analysis

August 2, 2025

Deep Learning Advances MRI Diagnosis of Brucella

August 2, 2025

POPULAR NEWS

  • Blind to the Burn

    Overlooked Dangers: Debunking Common Myths About Skin Cancer Risk in the U.S.

    60 shares
    Share 24 Tweet 15
  • Neuropsychiatric Risks Linked to COVID-19 Revealed

    43 shares
    Share 17 Tweet 11
  • Dr. Miriam Merad Honored with French Knighthood for Groundbreaking Contributions to Science and Medicine

    46 shares
    Share 18 Tweet 12
  • Study Reveals Beta-HPV Directly Causes Skin Cancer in Immunocompromised Individuals

    38 shares
    Share 15 Tweet 10

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Special Collection: 2024 Aging Innovation Conference

Lorlatinib’s Real-World Impact on ALK+ NSCLC

TrueBeam vs. Halcyon: Breast Cancer Radiotherapy Comparison

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.